The European Medicines Agency has said no to approving a new ... The drug - the first new treatment for 20 years - was controversially approved in the US in June. At the time, many scientists ...

About AVT23 AVT23 is a monoclonal antibody and proposed biosimilar to Xolair ® (omalizumab). AVT23 is an investigational compound and has not received regulatory approval in any country. Biosimilarity ...

The European Medicines Agency has approved use of Moderna's Covid vaccine for children aged between 12 and 17. It is the second Covid jab to be approved for adolescents by the EU's medicines ...

to European Medicines Agency (EMA) expected by early 2025 Conference call and webcast today at 8:00 a.m. ET BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company ...

The US-developed NOVAVAX vaccine against COVID-19 has been approved Monday by the European Medicines Agency (EMA), thus becoming the fifth drug of its kind to become available at a continental level.

First, Wegovy is a weight loss and cardiovascular drug already approved by the FDA in the U.S. that has recently also been ...

− Type II Variation Submission Based on the Positive HELIOS-B Phase 3 Study in which Vutrisiran Significantly Reduced the Risk of Death and Cardiovascular Events Relative to Placebo – "Today ...

Climate scientists working at the European Union's Copernicus Climate ... According to its ERA5 dataset, the agency said it was "virtually certain" that the annual temperature for 2024 will ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 years on ...

But eight years after its creation, Northvolt is on the verge of bankruptcy and has become a symbol of a European economy ... Expert from the Swedish Energy Agency, Greger Ledung, a specialist ...

Exelixis’s Cabometyx continues to drive revenue growth, prompting a raised 2024 forecast to $2.15–$2.2 billion. Read my EXEL ...